Showing 4211-4220 of 6411 results for "".
- Mindfulness and Self-compassion Training Improve QOL for AD Patientshttps://practicaldermatology.com/news/mindfulness-and-self-compassion-training-improve-qol-for-ad-patients/2461713/Online group mindfulness and self-compassion training improves quality of life in adults with atopic dermatitis (AD). In this randomized clinical trial of 107 adults with AD, mindfulness and self-compassion training in addition to usual care showed significantly greater improvement
- PathologyWatch Launches ‘Show Me Some Skin’ Campaign for Skin Cancer Awareness Monthhttps://practicaldermatology.com/news/pathologywatch-launches-show-me-some-skin-campaign-for-skin-cancer-awareness-month/2461696/
- Meet Zerigo 2.0: Upgraded System Allows Patients to Better Manage Psoriasis and Eczema at Homehttps://practicaldermatology.com/news/meet-zerigo-20-upgraded-system-allows-patients-to-better-manage-psoriasis-and-eczema-at-home-2/2461681/Zerigo Health is rolling out the Zerigo 2.0 ecosystem, the newest iteration of its digital health platform for the treatment and management of chronic skin conditions like eczema and psoriasis to employers, health plans, and their provide
- First Patient Dosed in Phase 2 Trial of ADX-629 in ADhttps://practicaldermatology.com/news/first-patient-dosed-in-phase-2-trial-of-adx-629-in-ad/2461650/Aldeyra Therapeutics, Inc.
- Phase 3 Studies Show Lebrikizumab Effective in Patients With Moderate-to-Severe Atopic Dermatitishttps://practicaldermatology.com/news/phase-3-studies-show-lebrikizumab-effective-in-patients-with-moderate-to-severe-atopic-dermatitis/2461630/After 16 weeks of treatment, lebrikizumab (Almirall) was effective in adolescents and adults with moderate-to-severe atopic dermatitis, according to two Phase 3 studies. The research was published in the New England Journal of
- LEO Pharma, ICON Enter a Strategic Partnership to Propel Clinical Trial Execution within Dermatologyhttps://practicaldermatology.com/news/leo-pharma-icon-enter-a-strategic-partnership-to-propel-clinical-trial-execution-within-dermatology/2461602/LEO Pharma and
- Fewer Cases of Melanoma, Cancers in Extracutaneous Sites Seen in Patients with Atopyhttps://practicaldermatology.com/news/fewer-cases-of-melanoma-cancers-in-extracutaneous-sites-seen-in-patients-with-atopy/2461591/Fewer cases of melanoma are observed in people with a history of atopic diseases, such as allergic asthma or rhinitis, than in nonatopic people, according to a new study in Melanoma Research. Specifically, the risk of melanoma in people with atopy was up to 50% lower than
- Meet TargetCool, CoolHealth's Solution to Post-Procedure Pain, Bruisinghttps://practicaldermatology.com/news/meet-targetcool-coolhealths-solution-to-post-procedure-pain-bruising/2461549/CoolHealth is entering the U.S. market with TargetCool. Leveraging tuneable cooling technology, TargetCool rapidly cools the skin, allowing providers to specifically set a “target” skin temperature down to the exact degree and
- Arcutis Enrolls First Patient in Phase 1b Alopecia Areata Study of ARQ-255https://practicaldermatology.com/news/arcutis-enrolls-first-patient-in-phase-1b-alopecia-areata-study-of-arq-255/2461458/The first subject has been enrolled in a Phase 1b study evaluating Arcutis’ ARQ-255, a topical suspension of ivarmactinib, a potent and specific janus kinase 1 (JAK1) inhibitor, for the treatment of alopecia areata. ARQ-255 has been specifically formulated with Arcutis’
- Artemis Health, Zerigo Health Partner to Help Employers and Health Plans Better Evaluate and Manage Chronic Autoimmune Skin Conditionshttps://practicaldermatology.com/news/artemis-health-zerigo-health-partner-to-help-employers-and-health-plans-better-evaluate-and-manage-chronic-autoimmune-skin-conditions/2461335/Artemis Health and Zerigo Health are joining forces to helps employers, advisors, and health plans evaluate and manage benefits for their members with chronic autoimmune skin conditions such as psoriasis and atopic dermatitis. “Benefits leaders are inundated by hundreds of point s